International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.

[1]  A. Tefferi,et al.  World Health Organization class-independent risk categorization in mastocytosis , 2019, Blood Cancer Journal.

[2]  M. Triggiani,et al.  The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. , 2019, The journal of allergy and clinical immunology. In practice.

[3]  P. Guglielmelli,et al.  Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. , 2018, Blood advances.

[4]  K. Roskin,et al.  Impact of somatic and germline mutations on the outcome of systemic mastocytosis. , 2018, Blood advances.

[5]  T. Haferlach,et al.  Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. , 2017, Blood.

[6]  P. Valent,et al.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. , 2017, Blood.

[7]  J. Zuber,et al.  CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. , 2017, Blood.

[8]  F. Awan,et al.  Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. , 2016, The New England journal of medicine.

[9]  P. Martus,et al.  Development and validation of the mastocytosis quality of life questionnaire: MC‐QoL , 2016, Allergy.

[10]  C. Brooks,et al.  CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value , 2016, Leukemia.

[11]  T. Haferlach,et al.  Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis , 2016, Leukemia.

[12]  S. Schoenberg,et al.  Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis , 2016, Leukemia.

[13]  B. Grosbois,et al.  Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. , 2015, Blood.

[14]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[15]  A. Órfão,et al.  The immunophenotype of mast cells and its utility in the diagnostic work‐up of systemic mastocytosis , 2015, Journal of Leukocyte Biology.

[16]  L. Pagano,et al.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Bindslev‐Jensen,et al.  Epidemiology of systemic mastocytosis in Denmark , 2014, British journal of haematology.

[18]  P. Valent,et al.  The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease , 2014, Allergy.

[19]  A. Kohlmann,et al.  Comprehensive mutational profiling in advanced systemic mastocytosis. , 2013, Blood.

[20]  A. Órfão,et al.  Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. , 2009, The Journal of allergy and clinical immunology.

[21]  A. Tefferi,et al.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. , 2009, Blood.

[22]  D. Metcalfe.  Mast cells and mastocytosis. , 2008, Blood.

[23]  J. Kinet,et al.  Case-Control Cohort Study of Patients' Perceptions of Disability in Mastocytosis , 2008, PloS one.

[24]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[25]  D. Metcalfe,et al.  Systemic mastocytosis. , 2004, Annual review of medicine.

[26]  M. Fiegl,et al.  Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease , 2002, International Archives of Allergy and Immunology.

[27]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[28]  P. Valent,et al.  Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. , 2001, Leukemia research.

[29]  A. Órfão,et al.  Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. , 2001, Leukemia research.

[30]  H. Kluin-Nelemans,et al.  Response to interferon alfa-2b in a patient with systemic mastocytosis. , 1992, The New England journal of medicine.